{
  "docId": "019de073-5c75-763a-a0f1-d995dc5da488",
  "docSlug": "01bee26c2c6ee992ec5e01a8e02dc689",
  "documentTitle": "Myovant Sciences | Results Presentation Deck | 34 slides",
  "authorId": "myovant-sciences",
  "authorName": "Myovant Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 34,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses icons to represent four distinct pillars of growth: product profile, market synergy, financial milestone, and strategic pipeline expansion.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-5c75-763a-a0f1-d995dc5da488/7",
  "deckHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488",
  "deckJsonHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488.json",
  "deckAnchorHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.06,
        "x": 0.07,
        "y": 0.267
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "326ef788-ed64-43f2-8fdc-827da02e0d66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.78,
        "x": 0.153,
        "y": 0.767
      },
      "kind": "list",
      "text": "Approval further enables MYOVANT's ability to achieve significant growth, while building our pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49a5703c-567a-432d-8e8c-3009e364f525",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.133,
        "w": 0.78,
        "x": 0.153,
        "y": 0.467
      },
      "kind": "list",
      "text": "New indication creates promotional synergies across uterine fibroids and endometriosis leading to a highly efficient launch, starting later this month",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a01bfc3-ee0e-4c37-8c89-585114c4079a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.133,
        "w": 0.78,
        "x": 0.153,
        "y": 0.267
      },
      "kind": "list",
      "text": "MYFEMBREE brings both significant efficacy and a well characterized safety profile for long-term¹ use, in a convenient one-pill, once-daily dose",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83af5693-dd8d-488d-b490-02f7b7a75877",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.067,
        "w": 0.78,
        "x": 0.153,
        "y": 0.667
      },
      "kind": "list",
      "text": "Approval triggers $100M milestone payment from Pfizer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec1b4efe-a27a-41d4-8a15-8050cf93b93e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.033,
        "w": 0.6,
        "x": 0.07,
        "y": 0.933
      },
      "kind": "source-note",
      "text": "(1) Up to 2 years. Full prescribing information for MYFEMBREE, including Black Box Warning, is available at www.myovant.com/myfembree-prescribing-information.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "653e5a84-baf8-4cdb-8d7b-ae1dbe2bf9d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.133,
        "w": 0.813,
        "x": 0.037,
        "y": 0.067
      },
      "kind": "title",
      "text": "Approval Contributes to Significant Growth Opportunity in 2022 and Beyond",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c0cf713-dfd2-42ac-bc72-e36793f61daa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b061a9eb-90da-4016-a0fc-6239c295f0b9",
      "evidence": "The document presents data on the impact of MYFEMBREE on daily activities and pain relief",
      "position": 0,
      "objective": "Highlight the need for effective treatment options",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}